Purpose: Evaluation of effectiveness and safety of ustekinumab in psoriatic arthritis after anti-TNFα failure.
Methods: We conducted a retrospective and monocentric study. The evaluation of articular and cutaneous effectiveness by the patient was made with numeric scale and satisfaction scale and by the physician during a rhumatological-dermatological consultation. The safety was analyzed by collecting the adverse effects.
Results: Nine patients with anti-TNF failure were included. Five of them stopped the treatment because of severe adverse effects. The mean duration treatment of ustekinumab was 24 months. Articular and cutaneous effectiveness were respectively 4.4/10 and 6.7/10. Two thirds of the patients were "satisfied" and one third could stop any analgesic treatment. The mean PASI score decreased from 8.4 to 1.7 after 3 months treatment. Only minor adverse effects were collected and there were no recidivism of the adverse effects observed with anti-TNFα.
Conclusion: Ustekinumab is an effective and safe alternative for patients with anti-TNFα failure in psoriatic arthritis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.therap.2015.07.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence of Autoimmune Diseases in Patients Treated With Immune Checkpoint Inhibitors: An Epidemiological Study Using A Global Network of Health Care Organizations.
ACR Open Rheumatol
January 2025
Jefferson Einstein Philadelphia Hospital, Philadelphia, Pennsylvania.
Objective: Evaluate prevalence of new onset autoimmune conditions (ACs) after commencement of immune checkpoint inhibitors (ICIs).
Methods: This retrospective observational study was done using TriNetX. Patients with neoplasm for which ICIs were approved were stratified into two groups based on ICI use.
Clinical features of inflammatory arthritis in daily practice-China's perspective.
Clin Rheumatol
January 2025
Department of Rheumatology and Immunology, Peking University People's Hospital, 11 Xizhimen South Street, Beijing, 100044, China.
Objective: This study aimed to analyze and compare the proportion of patients with different types of inflammatory arthritis and investigate the clinical characteristics, including symptoms and signs, medication choices, and disease activity, in the daily clinical practice of China.
Methods: Patients with inflammatory arthritis were recruited from 16 Grade-A tertiary hospitals between August 2021 and April 2022. The medical profiles, encompassing sociodemographic characteristics, clinical and laboratory date, were collected.
A Study on the Clinico-serological Features of Nail Psoriasis.
Indian Dermatol Online J
December 2024
Department of Dermatology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh, India.
Introduction: Nail psoriasis is a relatively unexplored clinical feature in the Indian population. Its correlation with cutaneous, musculoskeletal, and serological manifestations was analyzed.
Material And Methods: This study included 45 patients with clinically evident nail psoriasis.
A case of high tibial osteotomy in a patient with psoriatic arthritis.
Mod Rheumatol Case Rep
January 2025
Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Traditionally, patients with rheumatic diseases, such as rheumatoid arthritis (RA), were considered off-limits for joint-sparing surgery. In the present study, we report bilateral knee joints of psoriatic arthritis coexisting with osteoarthritis, with good, albeit short-term, results. 62-year-old woman was treated for psoriatic arthritis with a biologic (adalimumab).
View Article and Find Full Text PDFManagement of Systemic Anti-psoriatic Drugs in Psoriasis Patients with Concurrent Paraplegia or Tetraplegia: Insights From a 6-Year Multicenter, Retrospective Observational Study.
Dermatol Ther (Heidelb)
January 2025
Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Section of Dermatology, University of Messina, 98125, Messina, Italy.
Introduction: Patients with psoriasis (PsO) and permanent spinal cord injuries (SCI) resulting in paraplegia and tetraplegia may experience a higher rate of infections compared to patients with PsO without SCI. It can result in further challenges for therapeutic management with immunosuppressants (biological and non-biological treatments). Thus, we aimed to evaluate the rate of infections in patients with PsO and SCI treated with systemic immunosuppressants.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!